Epilepsy GTx Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Epilepsy GTx Limited - overview
Established
2022
Location
Canterbury, Kent, UK
Primary Industry
Biotechnology
About
Established in 2022 and based in Cambridge, UK, Epilepsy GTx operates as a late preclinical stage biotechnology research company that develops gene therapy for the treatment of seizures in patients. In December 2025, Epilepsy GTx Limited raised USD 33 million in series A funding from new investors XGEN Venture and British Business Bank, with participation from other unspecified investors. EpilepsyGTx develops gene therapies for focal refractory epilepsy (FRE). Their primary offering, EPY201, aims to provide seizure freedom for patients whose seizures persist despite treatment with multiple antiseizure medications.
Moreover, EPY201 utilizes an AAV9 capsid to deliver a transgene encoding an engineered Kv1. 1 potassium channel, which reduces neuronal excitability and epileptic activity. The company's approach involves the targeted delivery of gene therapy to the specific area of the brain where seizures originate. The company will use the December 2025 funding to advance gene therapy programs, support clinical trials, and expand manufacturing capabilities.
Current Investors
UCL Technology Fund, Health Technology Holding, British Business Bank
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.epilepsygtx.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.